Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab plus pembrolizumab versus docetaxel in previously treated metastatic NSCLC
NL-OMON60623Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Acasunlimab + pembrolizumab with Docetaxel (2 arms). Primary endpoint: Overall survival. Started Feb 2025; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60623.